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Abstract 
The pro-apoptotic BCL-2 family member BOK is widely expressed and resembles 
the multi-BH domain proteins BAX and BAK based on its amino acid sequence. 
The genomic region encoding BOK was reported to be frequently deleted in 
human cancer and it has therefore been hypothesized that BOK functions as a 
tumor suppressor. However, little is known about the molecular functions of BOK. 
We show that enforced expression of BOK activates the intrinsic (mitochondrial) 
apoptotic pathway in BAX/BAK-proficient cells but fails to kill cells lacking both 
BAX and BAK or sensitize them to cytotoxic insults. Interestingly, major portions 
of endogenous BOK are localized to and partially inserted into the membranes of 
the Golgi apparatus as well as the endoplasmic reticulum (ER) and associated 
membranes. The C-terminal transmembrane domain of BOK thereby constitutes a 
'tail-anchor' specific for targeting to the Golgi and ER. Over-expression of full-
length BOK causes early fragmentation of ER and Golgi compartments. A role for 
BOK on the Golgi apparatus and the ER is supported by an abnormal response of 
Bok-deficient cells to the Golgi/ER stressor brefeldin A. Based on these results, 
we propose that major functions of BOK are exerted at the Golgi and ER 
membranes and that BOK induces apoptosis in a manner dependent on BAX and 
BAK. 
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Introduction 
The intrinsic (mitochondrial) apoptotic pathway is stringently controlled by the BCL-2 
protein family, which is divided into three groups based on the ability to induce or 
antagonize apoptosis and the presence of up to four short conserved domains, termed 
BCL-2 homology domains (BH1-BH4) (1). The members of the pro-survival subgroup 
(BCL-2, MCL-1, BFL-1/A1, BCL-XL and BCL-W) inhibit apoptosis and contain all four BH 
domains (BH1-BH4) (2). The pro-apoptotic members are divided into two subgroups, the 
multi-BH domain containing BAX-like family (BAX, BAK and BOK), and the BH3-only 
proteins (BIM, BID, NOXA, BAD, PUMA, BIK, HRK and BMF) (3). The latter contain only 
a BH3 domain, which is essential for apoptosis initiation upon activation in response to 
apoptotic stimuli (4). By a series of complex and still controversially discussed protein-
protein interactions, activated BH3-only proteins transmit the apoptotic signal to BAX 
and BAK, which are essential for mitochondrial outer membrane permeabilization 
(MOMP) (5, 6). MOMP is commonly seen as the point-of-no-return in the intrinsic 
apoptotic pathway; it unleashes the activation of apoptotic caspases, which are 
responsible for the demolition of many vital cellular substrates and consequently the 
morphological changes observed during apoptosis (7, 8). 
Most BCL-2 family members are tail-anchored to the mitochondrial outer membrane via 
a C-terminal alpha-helical transmembrane domain (TMD) that serves both as a targeting 
and anchoring device (2, 9). However, several members, including BCL-2, BAX and 
BAK, are also present on other organelles, most notably the endoplasmic reticulum (ER), 
where they have been reported to be involved in the regulation of calcium homeostasis, 
autophagy and ER stress responses (2, 10-15). 
BOK (BCL-2-related ovarian killer) was identified in a yeast two-hybrid screen using 
MCL-1 as bait and was shown to selectively interact with MCL-1 and BFL-1/A1 but not 
with BCL-2 or BCL-XL (16, 17). Among the BCL-2 family members, BOK shows highest 
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evolutionary conservation (18, 19). Bok expression was first reported to be restricted to 
reproductive tissues (16). However, we have recently shown that BOK can be detected 
in most tissues, albeit in several at only relatively low levels (20). The BOK protein was 
found to localize to mitochondria, the ER as well as to the nucleus (18, 21, 22). 
Several studies, largely relying on protein over-expression, have shown that BOK can 
induce cell death; however, the exact mechanisms are poorly understood and may 
involve both caspase-dependent and -independent pathways (16, 17, 23).  Based on the 
high sequence similarity of BOK with BAX and BAK (particularly in the BH1-3 domains) it 
has been assumed that BOK might function similar to BAX/BAK (16, 17, 20-22, 24). 
However, the high resistance of cells lacking both BAX and BAK towards possibly all 
intrinsic apoptotic stimuli (25, 26), together with detectable BOK levels in those cells, 
raises the question whether BOK can substitute for the function of BAX and BAK.  
Using gene-targeting in ES cells, we have shown that mice develop normally in the 
absence of Bok and that young adult Bok-/- mice show no obvious abnormalities. 
Furthermore, Bok-/- hematopoietic cells responded normally to diverse classical apoptotic 
stimuli, such as cytokine deprivation or γ-irradiation (20). Interestingly, Beroukhim and 
colleagues have recently reported that the BOK gene is localized in a region of the 
genome that is frequently deleted in human cancer (27). It is therefore possible that BOK 
acts as a tumor suppressor. Loss of Bok did, however, not accelerate the development 
of pre-B/B-cell lymphoma in the Eµ-Myc transgenic mouse model (20). This result may 
indicate that Bok may play a role in tumor suppression in cells outside the lymphoid 
system, consistent with the observation that Bok expression in lymphocytes is low (20). 
In this study, we investigated the subcellular localization of over-expressed and 
endogenous BOK and its potential to kill cells in the presence or absence of BAX/BAK. 
We found that substantial portions of BOK protein are present on the Golgi and ER 
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membranes. Over-expressed BOK was found to cause early fragmentation of Golgi and 
ER compartments upstream of caspase activation. Interestingly, BOK failed to kill Bax-/-
Bak-/- doubly deficient cells and high BOK levels could not substitute for the combined 
loss of BAX and BAK in inducing apoptosis in response to stress stimuli. Finally, BOK-
deficient cells responded abnormally to brefeldin A, a drug that impacts the Golgi/ER, 
supporting a role for BOK within these subcellular compartments. Taken together, these 
results indicate that BOK plays important roles on the membranes of the Golgi and ER 
and activates the intrinsic apoptotic pathway in a manner dependent on BAX and BAK. 
 
Results 
BOK-induced apoptosis is largely BAX/BAK-dependent 
We have recently shown that BOK is widely expressed in the mouse ((20) and 
Supplementary Figure S1), therefore perhaps indicating that based on its resemblance 
to BAX and BAK it may play a role in apoptosis in many cell types. However, mice 
lacking both Bax and Bak present with severe phenotypic abnormalities in diverse 
tissues, such as epithelial, neuronal and hematopoietic ones. Moreover, cells derived 
from these mice are highly resistant towards possibly all intrinsic apoptotic stimuli (25, 
28), even though they do express endogenous BOK. This may indicate that BOK does 
not exert a major role overlapping with those of BAX and BAK. To investigate the 
function of BOK further, and given that over-expression of BOK was previously reported 
to induce apoptosis (16-18, 21-23), we examined whether BOK-induced apoptosis 
depends on the presence of BAX/BAK. 
Using an inducible expression system (29) or transient transfection, we first confirmed 
that BOK over-expression kills several non-transformed and transformed cells. As shown 
in Figure 1, SV40 large T antigen-immortalized mouse embryo fibroblasts (SV40 MEF) 
died upon induction of BOK, exhibiting classical features of apoptosis, including rounding 
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and detachment, plasma membrane blebbing, phosphatidylserine exposure, effector 
caspase activation and increased subG1 DNA content. Induction of EGFP expression 
did not kill these cells and 4-hydroxytamoxifen did not exert cytotoxicity. This shows that 
BOK over-expression can specifically kill these cells (Figure 1b and Supplementary 
Figure 2). Over-expressed BOK induced cytochrome c release and caspase-9 activation 
preceding caspase-3 processing (Figure 1e-h). Similarly, growth factor-dependent 
murine myeloid progenitors (FDM), the IL-3-dependent pro-B cell line BaF/3, human 
Jurkat T cell leukemia as well as HeLa cervical cancer derived cells were killed in 
response to BOK over-expression (Figure 2d, Supplementary Figure S3). This cell death 
could be inhibited by addition of the pan-caspase inhibitor Q-VD-OPh (Figures 1a, S3a 
and S3e). Importantly, BOK-induced cytochrome c release occurred upstream of 
caspase activation (Figure 1f). This indicates that BOK-induced cell killing proceeds via 
the intrinsic apoptotic pathway. BOK-induced killing was independent of the presence of 
endogenous BOK (Supplementary Figure S3f) and BOK over-expression killed MCL-1-
deficient MEF significantly faster than WT cells, further supporting the notion that BOK 
activates the intrinsic apoptotic pathway (Figure 1a). 
To investigate whether BOK-induced apoptosis was dependent on BAX and BAK, we 
over-expressed BOK in Bax-/-Bak-/- MEF and FDM. Although BOK over-expression could 
efficiently kill WT MEF and FDM, this largely (MEF) or completely (FDM) failed to kill 
cells lacking both BAX and BAK (Figures 2a, b, d). In contrast, MEF or FDM lacking only 
BAX or BAK, respectively, were normally sensitive to BOK-induced killing (not shown). 
Importantly, BOK over-expression also failed to sensitize Bax-/-Bak-/- MEF and FDM to 
classical apoptotic stimuli, including treatment with etoposide or staurosporine (Figure 2c 
and d). 
We next examined which protein-protein interactions are critical for BOK over-
expression-induced apoptosis. The D83G mutation in BAK was shown to prevent 
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homodimerization/-oligomerization and consequently abrogated its ability to kill Bax-/-
Bak-/- MEF (30). Intriguingly, BAK(D83G) was still capable of killing HEK293T cells (30), 
as was the corresponding BAX(D68A) mutant (31), indicating that these mutants can 
activate endogenous BAX/BAK. We found that FLAG-(WT)BOK co-immunoprecipitated 
HA-(WT)BOK, but this interaction was disrupted by a point mutation of the conserved 
aspartate76 residue within its BH3 domain (Figure 2e). Interestingly, BOK(D76A) retained 
its full ability to kill WT and Bok-/- cells, indicating that BOK may trigger apoptosis as a 
monomer (Figure 2f). No significant interaction was found by co-immunoprecipitation 
analysis between WT BOK and pro- or anti-apoptotic BCL-2 family members (Figure 3). 
Collectively, these results show that BOK over-expression induces apoptosis in 
BAX/BAK-proficient but not in BAX/BAK DKO cells, indicating that BOK may act 
upstream of BAX and BAK in the intrinsic apoptotic pathway. 
 
Over-expressed BOK localizes to the ER and Golgi apparatus 
When we analyzed the subcellular localization of over-expressed FLAG- or EGFP-
tagged BOK by confocal microscopy, we found that BOK only partially co-localized with 
mitochondrial markers but was also found on other intracellular membranes (Figure 4a 
and 5b). Using staining for organelle specific markers, we found that BOK was 
prominently associated with the membranes of the endoplasmic reticulum (ER) and its 
associated nuclear outer membrane (co-localization with calnexin) as well as with the 
Golgi apparatus (co-localization with cis-Golgi protein GM130 and trans-/medial-Golgi 
protein GalNAc-T2) (Figure 4a). In addition, over-expressed BOK showed vesicular 
localization patterns, particularly at later time points and upon blocking of apoptosis with 
Q-VD-OPh. This vesicular BOK partially co-localized with the early and recycle 
endosome markers RAB4 and RAB11, respectively, the late endosome marker RAB5a 
and was found in LysoTracker positive vesicles (acidic organelle marker) (Figure 4b and 
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Supplementary Figure S4). Interestingly, cells over-expressing BOK showed readily 
detectable changes in ER and Golgi morphology. The ER appeared swollen and 
fragmented (punctuated pattern) and the Golgi apparatus displayed weakened GM130 
staining at early time points and a fragmented pattern at later time points. These 
alterations clearly depended on over-expression of full length BOK, since these 
organelles were not affected in cells over-expressing EGFP fused to the TMD of BOK 
only (Figure 5). BOK-induced disruption of Golgi and ER-structures occurred upstream 
of caspase activation as it was also seen in the presence of Q-VD-OPh (Figure 4c).  
Taken together, these results show that major portions of over-expressed BOK are found 
on the ER-, Golgi and associated membranes and BOK over-expression rapidly leads to 
the fragmentation of these organelles in a caspase-independent manner. BOK may thus 
play a role in the dismantling of these organelles during apoptosis. 
 
The TMD of BOK is necessary and sufficient for Golgi and ER targeting 
The putative TMD of BOK atypically contains two positively charged amino acids, 
arginine200 and lysine203, weakening its hydrophobicity (Figure 5a). Similar to BCL-2, the 
net positive charge at the C-terminal end of BOK is +1, whereas others and we have 
shown that a net positive charge of ≥+2 is required for specific mitochondrial targeting (2, 
11, 32, 33). To test whether the TMD of BOK is a functional tail-anchor, we generated a 
TMD deletion mutant. Over-expressed EGFP-BOK∆TMD lacked organelle-targeting 
potential and, accordingly, was diffusely distributed in the cytosol and nucleus (Figure 
5b). To test whether the TMD of BOK is sufficient for organelle targeting, we fused the 
35 (or 27, not shown) C-terminal amino acids of BOK, encompassing its TMD plus 
flanking residues, to the C-terminus of EGFP. EGFP-TMD(BOK) efficiently co-localized 
with Golgi- and ER-markers but not with mitochondrial markers (Figure 5c and d). These 
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results show that the TMD of BOK is both necessary and sufficient for intracellular 
targeting to ER- and Golgi-membranes. 
 
Subcellular localization of endogenous BOK 
We next analyzed the subcellular localization of endogenous BOK in MEF by confocal 
microscopy. This confirmed a strong association of BOK with the Golgi apparatus and 
the ER, whereas endogenous BOK only partially co-localized with mitochondrial markers 
(Figure 6). The localization of endogenous BOK on the ER resembled the pattern seen 
for BCL-2, which is known to reside on the ER/nuclear outer membrane (11, 34, 35). 
However, in contrast to BOK, BCL-2 showed no Golgi-specific staining. To further 
investigate the localization of BOK on the Golgi apparatus, we treated MEF with 
brefeldin A (BFA), a drug that leads to Golgi fragmentation and is widely used to 
investigate Golgi apparatus dynamics (36). BFA treated MEF showed a rapid 
fragmentation of the Golgi into GM130 positive vesicular structures largely staining 
positive for BOK (Figure 6d). 
Subcellular fractionation of MEF followed by Western blotting revealed that a major 
portion of both over-expressed and endogenous BOK was present in the microsomal 
fraction positive for the Golgi marker GM130. BOK was further found in calnexin-positive 
ER-derived heavy membranes and in mitochondria-enriched fractions but not in cytosolic 
fractions (Figure 7a and b). In comparison, endogenous BAX and BAK, both of which 
were reported to also localize to ER membranes (37, 38), were found at only low levels 
in the microsomal fraction. The subcellular distribution of endogenous BOK was 
independently confirmed in freshly isolated mouse hepatocytes, a primary cell type that 
expresses relatively high amounts of BOK (Figure 7c).  
To determine whether organelle-targeted BOK was integrally inserted into the 
membranes, we treated membrane fractions isolated from MEF and primary hepatocytes 
Echeverry	  et	  al.	  
	   10	  
with alkaline solution (11). Both endogenous and over-expressed BOK were fully 
inserted into heavy membranes, whereas a portion of BOK present on microsomes was 
only loosely attached (Figure 7d and e). Trypsin-treatment of isolated membrane 
fractions completely degraded endogenous BOK protein, demonstrating that the epitope-
carrying N-terminus of BOK faces the cytosol (Figure 7f). This indicates that, similar to 
other BCL-2 family members, BOK may insert into organelle membranes with the bulk of 
the protein facing the cytosol. Furthermore, and in contrast to BAK, BAX or BCL-2, we 
found a significant portion of BOK in purified nuclear fractions (Figure 7g). Taken 
together, our microscopic and biochemical studies provide evidence that major portions 
of BOK localize to intracellular membranes other than the mitochondrial, in particular 
Golgi- and ER-membranes. 
 
Bok-deficient cells respond abnormally to the Golgi/ER-stressing drug brefeldin A 
As BOK was found on Golgi/ER membranes, we examined the response of WT and 
Bok-deficient cells to BFA, a drug that results in the collapse of the Golgi-complex into 
the ER, leading to ER stress and apoptosis (36, 39). Although BFA-induced Golgi-
fragmentation occurred normally in the absence of BOK (Supplementary Figure S5), 
BFA treated Bok-/- cells (MEF, mast cells and myeloid progenitors) responded with an 
abnormal ER stress response (Figure 8). Interestingly, BFA-treated cells died slightly but 
significantly faster in the absence of BOK. The same cells responded normally to other 
apoptotic stresses (e.g. etoposide, staurosporine), even though a minor but significant 
acceleration in cell death was also observed for tunicamycin-treated Bok-/- mast cells 
(Supplementary Figure S6). Western blot analysis revealed a disturbed ER stress-
response in Bok-/- MEF, as shown by defective upregulation of IRE1α and GRP78, and 
increase in active C-terminal Jun kinase (JNK), the BH3-only protein BIM, active 
caspase-3 and cleaved PARP. In conclusion, we observed an abnormal ER stress 
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response after BFA treatment in the absence of BOK, supporting a role for BOK within 
the Golgi and ER compartments. 
 
Discussion 
We show, in accordance with previous reports (16), that BOK over-expression can kill 
several cell lines tested. BOK activates the BCL-2-regulated (intrinsic) apoptotic 
pathway, as shown by characteristic morphological changes, cytochrome c release 
upstream of caspase-activation as well as caspase-9 and subsequent caspase-3 
activation. Involvement of the BCL-2-regulated apoptotic pathway is supported by our 
observation that MEF lacking MCL-1 were significantly more sensitive to BOK-induced 
killing than WT controls. However, even though BOK shows amino acid sequence 
similarities to BAX and BAK, it is not known whether BOK is a genuine BAX-like protein 
that would be able to substitute for the combined loss of BAX and BAK in triggering 
apoptosis. Numerous studies have shown that Bax-/-Bak-/- cells, including MEF or 
lymphocytes, are highly resistant to diverse apoptotic stimuli, even though they express 
detectable levels of endogenous BOK ((20) and Supplementary Figure S1). This strongly 
indicates that intrinsic apoptosis requires the presence of either BAX or BAK for its 
execution and hints at the inability of BOK to substitute for BAX/BAK function. 
We tested the effect of BOK over-expression in SV40 MEF and FDM cells. Whereas WT 
FDM were susceptible to BOK-induced killing, Bax-/-Bak-/- FDM were completely 
refractory to enforced BOK-expression. Bax-/-Bak-/- MEF were also largely protected from 
BOK-induced killing, although a minor extent of cell death was observed. In contrast to 
FDM cells, the pan-caspase inhibitor Q-VD-OPh (used at 25 µM) only partially protected 
WT MEF from BOK-induced killing. The low extent of cell death seen in the absence of 
BAX/BAK could therefore be due to additional, caspase-independent death pathways, 
which, in fact, have been suggested in early reports on BOK (16, 17, 40). Importantly, 
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Bax-/-Bak-/- MEF and FDM over-expressing BOK were still highly resistant to classical 
apoptotic stimuli. This indicates that BOK function cannot substitute for the combined 
loss of BAX and BAK and indicate that BOK may act upstream of BAX/BAK. This is in 
line with our observation that BOK over-expression increases the levels of the BH3-only 
proteins BIM and PUMA (Supplementary Figure S7). Alternatively, BOK may be 
activated by selective cell death stimuli that remain to be identified. 
BOK has been reported to interact with MCL-1 and BFL-1/A1 but not with BCL-2 or BCL-
XL (16, 17). A BH3-domain deletion mutant of BOK was unable to interact with MCL-1 
and BFL1/A1 but, surprisingly, still retained its killing activity (41). Although we did not 
detect interactions between BOK and other BCL-2 family members, we found that HA-
BOK and FLAG-BOK co-immunoprecipitated in a BH3 domain-dependent manner, as 
the interaction was disrupted by the BOK(D76A) point mutation. This supports the idea 
that, similarly to BAX and BAK, BOK may form homodimers/-oligomers. Interestingly, 
however, BOK(D76A) retained its ability to kill cells, indicating that BOK may induce cell 
death as a monomer. This is in contrast to BAX and BAK, where loss of killing function 
seems to invariably correspond with failure to oligomerize (30, 42, 43). 
We present evidence that the TMD of BOK is a targeting device both necessary and 
sufficient to target the protein to its intracellular destinations. Interestingly, the TMD of 
BOK has high affinity for Golgi and ER membranes. Accordingly, substantial portions of 
full-length BOK are localized on the ER and Golgi and associated membranes of the 
secretory system. Even though several BCL-2 family members, most notably BCL-2 but 
also BAX and BAK, were reported to bind to the ER/nuclear outer membranes where 
they exert specific functions (11, 34, 37, 44, 45), the Golgi targeting of BOK is of 
potential interest. Furthermore, whereas relatively minor fractions of BAX and BAK are 
detectable on the ER, a large portion of total BOK resides on the Golgi/ER. This 
indicates that BOK may exert specific functions on these organelles. Both BAX and BAK 
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were shown to interact with IRE1α at the ER and Bax-/-Bak-/- cells showed defective 
IRE1α-signaling and increased cellular damage upon ER stress (46). We observed a 
similar defective ER stress response in Bok-/- cells, which was most pronounced after 
treatment with brefeldin A, a drug that strongly impacts on the Golgi/ER compartments. It 
will be interesting to uncover the functions that BOK exerts at these locations, both in 
healthy and in dying cells. 
It is important to mention that our data do not exclude mitochondrial localization and 
function of BOK. In analogy to several BCL-2 family members localizing to multiple 
organelles, it is conceivable that BOK also localizes to mitochondria. Indeed, particularly 
when BOK was over-expressed, we found some co-localization with mitochondrial 
markers. Moreover, in subcellular fractionation experiments, BOK was also prominent in 
mitochondria-enriched fractions. However, these fractions were still significantly positive 
for the ER marker calnexin. Since the ER membranes interact with mitochondria through 
so-called mitochondria-associated membranes (MAM) (47), it is difficult to prepare MAM-
free mitochondrial fractions and, hence, further investigation is needed to quantify the 
exact amount of mitochondrial BOK.  
Irrespective of its subcellular localization, our data from Bax-/-Bak-/- DKO cells indicate 
that BOK cannot compensate for the combined loss of BAX and BAK in triggering 
MOMP and apoptosis. Instead, we show that BOK-induced apoptosis largely relies on 
the presence of BAX or BAK. BOK may therefore function upstream of BAX/BAK and 
may control the transmission of ER/Golgi-derived apoptotic signals to mitochondria. This 
hypothesis is supported by our observation that over-expressed BOK leads to the 
fragmentation of ER and Golgi upstream of caspase activation. However, when BOK is 
missing, the Golgi may be dismantled in conditions of stress in inappropriate manner, 
thereby causing increased ER stress and activation of BH3-only proteins, leading to 
apoptosis (48).  
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Little is known about the stress stimuli and mechanisms that lead to transcriptional or 
post-translational activation of BOK. In order to test whether BOK acts within the same 
pathway(s) as BAX and BAK or independently, triple knockout mice lacking Bok, Bax 
and Bak will have to be generated and their phenotype compared to those of Bax-/-Bak-/- 
animals. Besides its cytoplasmic localization, we also found BOK in purified nuclear 
fractions. Given the existence of BOK-deficient mice, possible functions of BOK within 
the nucleus, including putative non-apoptotic roles (e.g. as reported for trophoblast cell 
proliferation (49)) can now be analyzed. 
Finally, given that BOK has recently been identified as a candidate tumor suppressor 
(27) and increasing evidence emerges for non-apoptotic roles of BCL-2 family proteins, 
especially at non-mitochondrial sites, it will be interesting to test whether the putative 
tumor suppressor function of BOK is restricted to its pro-apoptotic function or whether it 
involves new functions yet to be discovered. 
 
Materials and Methods 
Mice and reagents 
Mice used for the isolation of bone marrow, primary hepatocytes and embryonic 
fibroblasts were maintained under specific pathogen-free conditions in individually 
ventilated cages. The generation of Bok-/- mice on an inbred C57BL/6 genetic 
background using C57BL/6 derived ES cells was described (20). Animal experiments 
were reviewed and approved by the animal experimentation review board of the canton 
of Bern (41/08 and BE31/11). 
High glucose Dulbecco's Modified Eagle Medium (DMEM, containing GlutaMAX™), 
RPMI 1640 medium (containing GlutaMAX™), William's E medium (containing 
GlutaMAX™), HEPES buffered saline solution (HBSS), trypsin solution 0.05% and 
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Penicillin/Streptomycin 100x stock solution were purchased from GIBCO (Life 
Technologies Europe, Zug, CH). Fetal calf serum (FCS, PAA Clone, endotoxin levels < 
1EU/mL) and puromycin were purchased from PAA (PAA Laboratories GmbH, AT). 4-
hydroxytamoxifen (4-OHT, #H7904), 2-mercaptoethanol, brefeldin A, dexamethasone 
and propidium iodide were purchased from Sigma-Aldrich Chemie GmbH (Buchs, CH). 
Q-VD-OPh was from SM Biochemicals (Anaheim CA, US). Staurosporine was 
purchased from Enzo LifeSciences AG (Lausen, CH). Recombinant His6-tagged GFP-
Annexin V was purified as described by Egger et al. (50). 
 
Expression constructs and site-directed mutagenesis 
Mouse Bok cDNA in the pCMV6 eukaryotic expression vector was purchased from 
ORIGENE (Rockville MD, US) with correct nucleotide sequence confirmed by DNA 
sequencing (Microsynth AG, Balgach, CH). Using a PCR based strategy employing the 
Pwo SuperYield polymerase (Roche Diagnostics AG, Rotkreuz, CH) a FLAG®-tag 
(DYKDDDDK) was added to the N-terminus of Bok and the resulting FLAG-Bok 
amplicon subcloned into the pcDNA3.1 expression vector using BamHI and EcoRI. 
Primer sequences: forward primer 5'-
CTGGGATCCATGGACTACAAGGACGATGACGATAAGGAGGTGCTGCGGCGCTCTT
C, reverse primer 5'-CTGGAATTCTCATCTCTCTGGCAACAACAGGAAG. Using the 
same strategy, the Bok C-terminal deletion mutant, FLAG-Bok∆TMD, was generated 
using the reverse primer 5'-CTGGAATTCTCAGTGGGAGCGGAAGCCAGGATC. The 
pEGFP-TMD(BOK) construct was generated by PCR amplifying the transmembrane 
domain (consisting of its 35 C-terminal amino acids) encoding sequence of the Bok gene 
using the template pCMV6/Bok(mm) with the forward primer 5’-
GATCTCGAGGTGGTCAGCACAGATC and the reverse primer 5’-
gcagaattctcatctctctggcaac and subcloned into the pEGFP(C3) mammalian expression 
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vector using XhoI and EcoRI. FLAG-Bok and FLAG-Bok∆TMD cDNA were subcloned 
from FLAG-Bok/pcDNA3.1 and FLAG-Bok∆TMD/pcDNA3.1 into the pF-5xUAS-SV40-
puro-GEV16 lentiviral vector using BamHI and XbaI/NheI or into the pEGFP(C3) 
expression vector using HinDIII and EcoRI. The Bok(D76A) single amino acid 
substitution was introduced into FLAG-Bok/pcDNA3.1 using QuikChange® Lightening 
Site-Directed Mutagenesis Kit (Agilent Technologies, Basel, CH) following the 
manufacturer’s instructions; forward primer: 5'-
CTGCGCTTGGGAGCTGAGCTGGAGCAG, reverse primer 5'-
CTGCTCCAGCTCAGCTCCCAAGCGCAG. The coding sequences of all subcloned or 
mutated plasmids was verified by DNA sequencing (Microsynth AG, Balgach, CH). 
 
Cell culture  
Bax-/-Bak-/- and matching wildtype SV40 LT-immortalized mouse embryo fibroblasts 
(MEF) were kindly provided by Dr. Christoph Borner (Freiburg, Germany). Primary 
C57BL/6 wildtype and Bok-/- MEF were isolated from 14.5-day-old embryos and 
immortalized with SV40 LT/pSG5. At least three independent lines, each derived from a 
different embryo were generated for each genotype. WT, Bax-/-, Bak-/- and Bax-/-Bak-/- 
FDM cells were kindly provided by Dr. Paul Ekert (Melbourne, AU). All cells were 
cultured at 37°C in a humidified 5% CO2 atmosphere. HeLa cells were cultured in 
DMEM/GlutaMAX™ high glucose medium supplemented with 10% FCS and 
penicillin/streptomycin. SV40 immortalized MEF were cultured in DMEM/GlutaMAX™ 
high glucose medium supplemented with 5% FCS and penicillin/streptomycin.  
 
Isolation and cultivation of primary hepatocytes  
Primary mouse hepatocytes were isolated from 6- to 12-week-old mice by a collagenase 
perfusion based method as described in (51). The purity of isolated hepatocytes was 
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routinely >95%, as judged by cellular morphology of attached cells. Isolated hepatocytes 
were plated on gelatin-coated flasks in William's E medium supplemented with 10% 
FCS, 100 nM dexamethasone, 2 mM L-glutamine and 1% penicillin/streptomycin 
solution. Upon adherence of the cells (after 4 h), cells were washed and experiments 
immediately started in complete William's E medium (without dexamethasone) at 37°C 
under 5% CO2.  
 
Generation of SCF-condHoxb8 cell lines and bone marrow-derived mast cells 
See Online Supplementary Section 
 
Transient transfection, immunofluorescence staining and confocal microscopy 
HeLa cells were grown on 12-mm glass coverslips and transiently transfected with 0.4 
µg of plasmid DNA and 1.6 µ L Fugene HD transfection reagent (Roche Diagnostics, 
Rotkreuz, CH) in 24-well plates. SV40 immortalized MEF were transfected with 0.4 µg of 
plasmid DNA and 1.6 µL Metafectene Pro (Biontex Laboratories GmbH, DE). At various 
times after transfection, cells were stained with 370 nM MitoTracker Deep Red 633 or 
500 µ M LysoTracker Red DND-99 (Invitrogen), fixed for 10 min with 4% 
paraformaldehyde, permeabilized with 0.05% saponin for 5 min and treated with ice-cold 
acetone for 10 min. The cells were then incubated over night at 4°C with the following 
primary antibodies diluted in PBS containing 1% bovine serum albumin: mouse anti-
FLAG® (clone M2, # F1804) and rabbit anti-calnexin (#C4731) from Sigma-Aldrich, 
rabbit anti-DYKDDDDK tag, rabbit anti-BOK (described in (20); adsorbed on PVDF 
membrane containing Bok-/- MEF lysate for IF applications), mouse anti-mouse BCL-2 
(clone 10C4, BioLegend), mouse anti-cytochrome c (clone 6H2.B4) and mouse anti-
GM130 (clone 35/GM130) from BD Biosciences. Secondary antibodies, Alexa Fluor 488- 
or 555-conjugated goat anti-mouse or goat anti-rabbit IgG (Life Technologies) antibodies 
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were added for 1 h at RT. Nuclear DNA was stained using 2 µg/mL Hoechst 33342 
(Sigma-Aldrich). Coverslips were mounted using Glycergel (Dako) or Prolong Gold 
antifade reagent (Life Technologies). Images were acquired using a Zeiss LSM 510 
laser confocal microscope with a 63x oil immersion objective and analyzed using the 
IMARIS software. 
 
Quantification of cell death by flow cytometry 
Cells were washed with Annexin V staining buffer (150 mM NaCl, 4 mM KCl, 2.5 mM 
CaCl2, 1 mM MgSO4, 15 mM HEPES pH 7.2, 2% FCS and 10 mM NaN3) and incubated 
with GFP-Annexin V diluted in staining buffer for at least 20 min on ice in the dark. Cells 
were then washed in Annexin V staining buffer and resuspended in 200 µL staining 
buffer. Propidium iodide was added to a final concentration of 2 µ g/mL and cells 
examined by flow cytometry using a FACS CaliburTM. GFP-Annexin V- and propidium 
iodide negative cells were considered as viable cells.  
 
Immunoprecipitation  
7x105 HEK 293T cells were seeded in 6-well plates and transfected on the following day 
with a total of 2 µg DNA plus transfection reagent (FUGENE HD, Roche Diagnostics) at 
a ratio of 1:4. Cells were lysed in 300 µL IP lysis buffer (50 mM Tris/HCl pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, complete protease inhibitor cocktail (Roche 
Diagnostics) and 1 µg/ml pepstatin) for 15 min on ice and lysates cleared by 
centrifugation. Lysates were pre-cleared using 50 µL of a 50% slurry of Protein G 
sepharose beads (GE Healthcare) for 1 h at 4°C on a rotating wheel and then incubated 
with either mouse anti-FLAG (clone M2, Sigma-Aldrich) or rat anti-HA (clone 3F10, 
Roche Diagnostics) antibodies for 2 h on ice. 50 µL of protein G sepharose beads (50% 
Echeverry	  et	  al.	  
	   19	  
slurry) were added and the mixture incubated at 4°C for a minimum of 2 h on a rotating 
wheel. Beads were washed three times in IP lysis buffer and boiled for 5 min in 50 µL of 
2x Lämmli buffer containing 100 mM DTT.   
 
Subcellular fractionation 
Subcellular fractionation was performed as described in (11). Briefly, a total of 1x107 
SV40 immortalized MEF or 5x106 primary hepatocytes were harvested, washed twice in 
phosphate-buffered saline (PBS) and resuspended in MSH-MD buffer (210 mM 
mannitol, 70 mM sucrose, 20 mM HEPES, 1 mM EDTA, pH 7.4, MgCl2, 2 mM DTT) 
supplemented with protease inhibitor cocktail (COMPLETE, Roche), 1 µg/mL pepstatin, 
2 mM sodium orthovanadate and 50 mM sodium fluoride). Cells were mechanically lysed 
by passing them through a 23G (MEF) or 25G (hepatocytes) needle. Nuclei and cellular 
debris were removed by centrifugation at 500x g for 5 min. The post-nuclear supernatant 
(PNS) was centrifuged at 10’000 for 15 min, and the resulting crude mitochondrial pellet 
washed twice in PBS. To further purify mitochondria, crude mitochondria were laid on 
top of a 1-2 M linear sucrose gradient and ultracentrifuged at 50’000 x g for 90 min. 
Enriched mitochondria, which banded at a region corresponding to 1.4 M sucrose, and a 
visible band at about 1.0 M sucrose, containing ER-derived heavy membranes, were 
carefully collected and diluted to 0.25 M sucrose prior to centrifugation at 50’000 x g for 
30 min. The resulting pellets were solubilized in hot H8 buffer (20 mM Tris/HCl pH 7.5, 
2mM EGTA, 2mM EDTA and 1 % SDS, 1mM DTT, protease inhibitor cocktail 
(COMPLETE, Roche), 1 µg/mL pepstatin, 2 mM sodium orthovanadate and 50 mM 
sodium fluoride). Centrifugation of the post-mitochondrial supernatant (PMS) at 100'000 
x g for 30 min yielded the microsomal pellet (P100) and the cytosolic fraction (S100). The 
microsome pellet was washed three times in MSH-MD buffer and lysed in hot H8 buffer. 
Nuclear fractionation was performed as described in Rosner et al. (52). Protein 
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concentration was measured using the Bradford assay. A total of 25 µ g protein per 
fraction was separated on denaturing SDS-PAGE gels and analyzed by Western 
blotting. 
 
Sodium carbonate extraction (alkaline treatment) and trypsin treatment 
Crude mitochondrial (P10) and microsomal (P100) fractions from SV40 immortalized MEF 
or primary hepatocytes were prepared as described above, resuspended in 0.1 M 
sodium carbonate solution (pH 12) and incubated for 20 min on ice. After centrifugation 
at 20'000 x g for 15 min at 4°C, the supernatant (containing the alkali-extractable 
proteins) was titrated back to a neutral pH with 1 M HCl. The pellet (containing the alkali-
resistant fraction) was washed three times in MSH-MD buffer and then solubilized in hot 
H8 buffer. 10 % of each fraction was used for a total lysate control. For trypsin 
treatments, crude mitochondrial and microsomal fractions were resuspended in complete 
MSH Buffer-MD and left on ice for 30 min with or without 0.1 mg/mL Trypsin. Protein 
concentration was measured using the Bradford assay. A total of 25 µ g protein per 
fraction was separated on denaturing SDS-PAGE gels and analyzed by Western 
blotting. 
 
Gel electrophoresis and immunoblotting 
Total protein extracts were prepared in a lysis buffer containing 50 mM Tris/HCl pH 7.4, 
150 mM NaCl, 1% NP-40, 0.1 % SDS, complemented with protease inhibitors (Roche 
COMPLETE protease inhibitor cocktail plus 1 µg/mL pepstatin) and phosphatase 
inhibitors (2 mM sodium orthovanadate and 50 mM sodium fluoride). Protein 
concentration was determined using a BCA assay (Thermo Scientific) and proteins were 
denatured by adding 4x reducing (100 mM DTT) Lämmli buffer and boiling the samples 
for 5 min. A total of 30 µg protein per extract was separated on denaturing SDS-PAGE 
Echeverry	  et	  al.	  
	   21	  
gels. Proteins were transferred on PVDF transfer membranes (0.45 µ m, Merck 
Millipore). For Western blotting, membranes were probed with the following primary 
antibodies: mouse anti-BCL-2 (clone 10C4, BioLegend); rabbit anti-GRP78/BIP and rat 
anti-BIM (clone 3C5) from Enzo LifeSciences; rabbit anti-PUMA (Pro-Sci, #3043); rabbit 
anti-calnexin (#C4731), mouse anti-tubulin (clone B-5-1-2) and mouse anti-FLAG® (M5) 
from Sigma-Aldrich; rabbit anti-caspase-3 (#9662), rabbit anti-active caspase-3 (#9661), 
rabbit anti-active caspase-7 (#9491), rabbit anti-IRE1α (clone 14C10), rabbit anti-
JNK/SAPK(#9252) and mouse anti-phospho-JNK/SAPK (clone G9, #9255) from Cell 
Signaling Technology; rabbit anti-BAX (#sc-493) from Santa Cruz Biotechnologies;  
mouse anti-cytochrome c (clone 7h8.2C12) and mouse anti-PARP (clone C2-10) from 
BD Biosciences; mouse anti-porin (clone 89-173/016) from Calbiochem; mouse anti-
GAPDH (clone 6C5) and rabbit anti-BAK (Bak NT) from Merck Millipore; rat anti-mouse 
MCL-1 (clone 14C11, kind gift from Dr. D. Huang, Melbourne, AU); rabbit polyclonal 
antibody raised against amino acids 19-32 of mouse BOK (described in (20)) and a 
rabbit monoclonal anti-BOK (RabMab BOK-1-5, raised against aa 19-32 of mouse Bok). 
Secondary antibodies specific to mouse, rat or rabbit IgG that had been coupled to horse 
radish peroxidase were obtained from Jackson ImmunoResearch Laboratories and 
signals were detected by enhanced chemiluminescence (ECL Western blotting 
substrate, Thermo Scientific and Luminata Forte, Merck Millipore) and detected on 
photosensitive film (ECL Hyperfilm, GE Healthcare). 	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Figure Legends 
Figure 1. Over-expressed BOK activates the intrinsic apoptotic pathway in SV40 
immortalized MEF. (a) SV40 immortalized WT and Mcl-1-/- MEF/5xUAS-FLAG-BOK 
cells were treated as indicated with 4-OHT (0.1 µM) and Q-VD-OPh (25 µM) for 24 or 48 
h and viability assessed by GFP-Annexin V/PI staining and flow cytometry. Data are 
presented as means +/- SD from three independent experiments. Induction of FLAG-
BOK in SV40 immortalized WT (see h) and Mcl-1-/- MEF was controlled by Western 
blotting. (b) SV40 immortalized WT MEF/5xUAS-FLAG-BOK and WT MEF/5xUAS-
EGFP cells were treated with 4-OHT (0.1 µM) for 24 or 48 h and viability assessed by PI 
staining and flow cytometry. Data represent means +/- SD from 6 (FLAG-BOK) and 5 
(EGFP) independent experiments, respectively. (c) Wide field micrographs of WT 
MEF/5xUAS-FLAG-BOK cells induced for 48 h with 0.1 µM 4-OHT. White arrows 
indicate apoptotic cells characterized by plasma membrane blebbing, rounding and 
detachment). (d) Representative dot plots (n ≥ 6) of GFP-Annexin V/PI staining of 
MEF/5xUAS-FLAG-BOK cells with or without FLAG-BOK induction for 48 h. (e) Confocal 
micrographs of WT MEF transiently transfected with EGFP-BOK for 9 h and 
immunostained with an antibody against cytochrome c. (f) WT MEF were transfected 
with expression constructs for EGFP or FLAG-BOK, in the absence or presence of 20 
µM Q-VD-OPh, for 9 h and percentages of EGFP- or FLAG-BOK positive cells with 
released cytochrome c determined by counting 100 cells for each condition. Data 
represent means +/- SD of 3 independent experiments. (g) WT MEF/5xUAS-FLAG-BOK 
cells were left untreated or treated with 0.1 µM 4-OHT for 14 h. Active caspases were 
covalently labeled with biotinylated X-VAD-fmk, pulled down with streptavidin-sepharose 
beads and Western blots probed for caspase-9 and caspase-3. Whereas active 
caspase-9 is pulled down, no signal for active caspase-3 could be detected at this 
specific time point. (h) WT MEF/5xUAS-FLAG-BOK cells were treated with 4-OHT (0.1 
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µM) for the indicated times and total protein lysates analyzed by Western blotting using 
anti-BOK and anti-caspase-3 antibodies. (i) Representative histograms (n ≥ 3) showing 
DNA content of WT MEF/5xUAS-FLAG-BOK with or without FLAG-BOK induction (t = 24 
h). The cell population with fragmented genomic DNA is indicated as subG1. 
Significance values were determined by paired Student's t-Test. ***: p<0.005; **p<0.01;  
*: p<0.05.  
  
Figure 2. BOK-induced apoptosis is largely BAX/BAK dependent. (a) FLAG-BOK 
was induced in SV40 immortalized WT and Bax-/-Bak-/- MEF/5xUAS-FLAG-BOK cells by 
addition of 0.1 µ M 4-OHT. Cell death was determined after 48 h by flow cytometric 
analysis (after staining with GFP-AnnexinV and PI). Data are presented as means +/- 
SD from ≥3 independent experiments. (b) WT and Bax-/-Bak-/- SV40 MEF were 
transduced with CAD-G-Whiz empty vector (CGW) or CGW/FLAG-BOK for 40 h and 
apoptosis of EGFP-positive cells measured by flow cytometry (Cherry-Annexin V positive 
cells). Data are presented as means +/- SD from 3 independent experiments. FLAG-
BOK expression and correct genotypes were verified by Western blotting, using 
antibodies to BOK, BAX and BAK. (c) FLAG-BOK was induced in Bax-/-Bak-/- 
MEF/5xUAS-FLAG-BOK cells for 24 h, followed by treatment with 10 nM staurosporine 
or 10 µg/mL etoposide for an additional 24 h. Cell death was quantified as described in 
(a). WT SV40 MEF treated with the same concentration of drugs for 24 h are shown as a 
control. Data represent means +/- SD from 3 independent experiments. (d) Survival of 
WT and Bax-/-Bak-/- FDM/5xUAS-FLAG-BOK cells with or without induction of FLAG-
BOK expression (upper panel). Surviving cells were determined by flow cytometry and 
data represent GFP-Annexin V/PI double-negative cells. Data represent means +/- SD 
from 3 independent experiments. Lower panel: FLAG-BOK was induced for 8 h in Bax-/-
Bak-/- FDM/5xUAS-FLAG-BOK cells, followed by treatment with 100 nM staurosporine 
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for an additional 24 h. Data represent means +/- SD from ≥3 independent experiments. 
FLAG-BOK expression and correct genotypes were verified by Western blotting, using 
antibodies to FLAG, BOK (RabMab BOK-1-5), BAX and BAK. (e) Co-
immunoprecipitation assay in HEK 293T cells transiently co-transfected for 14 h with HA-
BOK/pcDNA3 and FLAG-BOK/pcDNA3 or FLAG-BOK(D76A)/pcDNA3. Anti-FLAG and 
non-specific mouse IgG1 (isotype control) immunoprecipitates were probed by Western 
blotting using HA- and FLAG-specific antibodies. (f) Viability of WT and Bok-/- SV40 MEF 
upon induction of FLAG-BOK(D76A) was determined by GFP-Annexin V/PI negativity by 
flow cytometry. Induction of FLAG-BOK(D76A) was controlled by Western blotting using 
anti-BOK antibody. Data are presented as means +/- SD of ≥ three independent 
experiments. Significance was determined by Student's t-Test (***p<0.005, **p<0.01 and 
*p<0.05; n.s.: not significant). 
 
Figure 3. BOK does not co-immunoprecipitate with other BCL-2 family members. 
(a) HA-BOK or HA-BAK were transiently co-expressed with FLAG-tagged MCL-1, BCL-
XL, BCL-2 or BCL-W in HEK 293T cells. Immunoprecipitates (C: protein G sepharose 
beads only; F: anti-FLAG; H: anti-HA) were probed by Western blotting with anti-FLAG 
and anti-HA antibodies. (b) HA-BOK was transiently co-transfected with FLAG-BAX or 
FLAG-BAK. Anti-FLAG immunoprecipitates were probed by Western blot using anti-HA 
and anti-FLAG antibodies.  
 
Figure 4. Over-expressed BOK mainly localizes to membranes of the endoplasmic 
reticulum, Golgi apparatus and associated membranes. (a) Representative confocal 
scanning micrographs of HeLa cells transiently transfected with FLAG-BOK/pcDNA3 for 
18 h and stained with organelle-specific antibodies against calnexin (endoplasmic 
reticulum) or GM130 (Golgi matrix), MitoTracker Deep Red 633 (mitochondria), 
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GalNAc-T2-CFP (trans and medial Golgi) and Hoechst 33342 (nuclei). (b) HeLa cells 
were transfected with pEGFP-BOK for 8 h. Images were taken at real time. EGFP-BOK 
is found in vesicular patterns and partially co-localizes with the acidic organelle marker 
LysoTracker (acidic organelles), as indicated by white arrows. FLAG-BOK and GFP-
RAB4Q67L-GFP (constitutive active mutant, endosomal marker) were co-expressed in 
HeLa cells for 22 h. Partial co-localization is indicated by white arrows and in the 
magnified inlet. (c) HeLa cells stably expressing GaLNAc-T2-CFP (specific marker for 
trans and medial Golgi (53)) were transfected with FLAG-BOK/pcDNA3 for 21 h in the 
presence of 25 µ M Q-VD-OPh. Cells were stained with antibodies to calnexin and 
MitoTracker Deep Red 633. 40 Z-stacks were acquired and GaLNaC-T2-CFP channel 
iso-surface 3D Golgi reconstruction was performed using the IMARIS software. Cells 
expressing FLAG-BOK (white arrows) show weakened GalNAc-T2-CFP signal intensity, 
correlating with increased Golgi dissociation and fragmentation compared to non-
transfected cells. 
 
Figure 5. The transmembrane domain of BOK is necessary and sufficient for 
membrane targeting. (a) Amino acid sequences of the C-terminal transmembrane 
domains (TMD) of BOK, BCL-2, BCL-X, BAX and BAK. Positively charged amino acids 
are printed in bold. (b) Confocal scanning micrographs of HeLa cells and SV40 
immortalized Bok-/- MEF transfected with pEGFP-BOK∆TMD for 18 and 8 h, respectively, 
and stained as indicated. pEGFP-BOK∆TMD shows cytosolic and nuclear localization 
(Hoechst 33342, blue). EGFP-(WT)BOK is shown as control. (c) HeLa and 
HeLa/GalNAc-T2-CFP cells were transfected with pEGFP-TMD(BOK) for 24 h and 
stained with antibodies to calnexin (ER), MitoTracker Deep Red 633 (mitochondria) 
and Hoechst 33342 (DNA). EGFP-TMD(BOK) localizes extensively to Golgi membranes 
and ER membranes. (d) Confocal micrographs of SV40 immortalized WT MEF 
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transiently transfected with GFP-TMD(BOK) for 24 h and stained with the indicated 
organelle markers.  
 
Figure 6. Endogenous BOK strongly associates with the Golgi and ER 
compartments. (a-c) Confocal scanning micrographs of SV40 immortalized WT MEF 
stained with Hoechst 33342 (nuclei) and antibodies against BOK, GM130 (cis-Golgi 
marker), BCL-2 and cytochrome c. (d) WT SV40 MEF were treated with 0.3 µg/mL 
brefeldin A for 15 h and stained with anti-BOK and anti-GM130 antibodies and Hoechst 
33342. (e) SV40 immortalized Bok-/- MEF were stained with antibodies to BOK and 
Hoechst 33342. 
 
Figure 7. Analysis of the localization of over-expressed and endogenous BOK by 
subcellular fractionation and membrane insertion assays. Anti-BOK Western blots 
of subcellular fractions prepared from SV40 immortalized WT MEF/5xUAS-FLAG-BOK 
cells after FLAG-BOK induction with 0.1 µM 4-OHT for 14 h (a), SV40 WT MEF (b) and 
primary hepatocytes freshly isolated from young adult C57BL/6 (WT) mice (c). 
Membranes were re-probed with antibodies to mouse BCL-2, MCL-1, BAX and BAK for 
comparison. Re-probing of the membranes with antibodies to Porin or cytochrome C 
(mitochondria), calnexin (ER), GM130 (Golgi) and GAPDH (cytosol) served as controls 
for the purity of the subcellular fractions. Heavy (P10) and light (P100) membrane 
fractions from SV40 WT MEF (d) and mouse primary hepatocytes (e) were extracted 
directly with detergent (total) or first treated with sodium carbonate solution (pH 12) to 
remove loosely attached membrane proteins. Remaining membrane proteins were lysed 
in detergent and all fractions analyzed by Western blotting for endogenous BOK and 
indicated proteins that served as controls for integrally inserted membrane proteins 
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(Porin, BAK, BCL-2), or loosely attached and soluble proteins (BAX, GAPDH). BiP and 
PDI are luminal ER proteins and probing for them served as a control for vesicle 
integrity. (f) Heavy and light membranes were prepared from SV40 WT MEF and 
membrane proteins facing the cytosol, including endogenous BOK, were digested with 
0.01% trypsin. (g) Purified nuclear and cytoplasmic fractions were prepared from SV40 
WT MEF. A large portion of endogenous BOK was found in the purified nuclear fraction. 
The purity of the fractions was controlled by re-probing the membrane with antibodies 
against Histone H3 and PARP (nuclear) as well as Tubulin and GAPDH (cytoplasm). In 
contrast to BOK, no endogenous BCL-2, BAX or BAK could be detected in the nuclear 
fraction. 
 
Figure 8. BOK-deficient cells show an atypical response to treatment with 
brefeldin A. (a) The survival of SV40 immortalized WT, Bok-/- and Bax-/-Bak-/- MEF 
treated with the indicated doses of brefeldin A for 24 h was quantified by flow cytometry 
(GFP-Annexin V/PI negative cells). (b) Time kinetics of cell survival of SV40 WT and 
Bok-/- MEF treated with 0.5 µg/mL brefeldin A with or without 25 µM Q-VD-OPh. (c) WT 
and Bok-/- SCF-condHoxb8 immortalized myeloid progenitors were treated with the 
indicated doses of brefeldin A for 18 h. Cell survival was determined by GFP-Annexin 
V/PI staining followed by flow cytometric analysis. (d) Brefeldin A dose response curves 
(treatment for 24 h) of ex vivo generated bone marrow-derived mast cells (BMMC) 
derived from WT or Bok-/- mice. (e) Western blot analysis of protein lysates prepared 
from SV40 WT and Bok-/- MEF that had been treated with 3 µg/mL brefeldin A for the 
indicated times. Data are representative of 3 independent experiments using different 
SV40 immortalized MEF lines. All quantitative data (dose responses and time kinetics) 
are presented as means +/- SD of at least five (MEF) or three (BMMC, SCF-condHoxb8) 
independent experiments, respectively. Three independent lines (each derived from a 
Echeverry	  et	  al.	  
	   34	  
different embryo) were used for SV40 immortalized WT and Bok-/- MEF, respectively. 
Significance was determined by unpaired Student's t-Test (***p<0.005, **p<0.01 and 
*p<0.05).  
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ONLINE SUPPLEMENTARY INFORMATION 
Supplementary Material And Methods 
Production of lentiviral particles and transduction of cell lines 
The coding sequence of the gene of interest was cloned into the 4-OHT-inducible 
lentiviral vector pF-5xUAS-SV40-puro-GEV16 (1) via BamHI and NheI. pMD2.VSV-G 
(envelope coding sequence):pCMVδR8.2 (packaging elements):pF-5xUAS-GI-
Sv40puro-Gev16 (gene of interest) were co-transfected (total of 5 µg of DNA) at a ratio 
of 2:5:3 in 10-cm tissue culture dishes using FUGENE HD transfection reagent (Roche 
Diagnostics, Rotkreuz, CH). Lentiviral particles were harvested from the medium 24 and 
36 h later, pooled and passed through a 0.2 µm filter and used fresh for infection or 
stored in aliquots at -80°C. Target cell lines were transduced in the presence of 8 µg/mL 
polybrene by spin infection (500x g, 90 min, 30°C). Successfully transduced cells were 
selected with puromycin for a minimum of three weeks. Induction of expression of the 
gene of interest was achieved by addition of 100 nM 4-OHT. 
 
Generation of SCF-dependent conditional Hoxb8-immortalized neutrophil/ 
macrophage progenitor lines 
The protocol is based on the method described by Wang et al. (2), with the major 
modification of using a different inducible expression system (1). In this lentivirus based 
expression system, untagged Hoxb8, which is under the control of the 5xUAS yeast 
promoter, is induced by constitutively expressed GEV16 transcription factor (GAL4-
DBD_ER-LBD T2 mutant_VP16 TD) upon addition of 4-OHT (1, 3). Bone marrow-
derived hematopoietic progenitors were isolated from sacrificed WT or Bok-/- mice by 
magnetic bead based depletion of cells expressing lineage specific surface markers (BD 
IMagTM mouse hematopoietic progenitor cell enrichment set-DM, BD Biosciences) 
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following the manufacturer’s instructions. 5x105 lineage marker+ depleted cells were 
incubated for 36 h in complete RPMI Medium (RPMI 1640/GlutaMAX™ supplemented 
with 10% FCS, 1% penicillin/streptomycin solution and 50 µM 2-mercaptoethanol). Cells 
were then transduced with pF-5xUAS-Hoxb8(mm)-SV40-puro-GEV16 lentiviral particles 
(see above) by spin-infection for 2 h at 1'000 rpm at 30°C in the presence of 8 µg/mL 
polybrene. Cells were subsequently grown in complete RPMI medium supplemented 
with murine stem cell factor, SCF (added as 10% of CHO/SCF(mm)-conditioned 
supernatant) and 100 nM 4-OHT to switch on Hoxb8 expression. Successfully 
transduced cells were selected in 1.0 µg/mL puromycin for 4 weeks, resulting in the 
outgrowth of SCF-dependent conditional Hoxb8-immortalized myeloid progenitor cell 
lines, termed SCF-condHoxb8. 	  	  
In vitro growth of bone marrow-derived mast cells 
Bone marrow-derived mast cells (BMMC) were generated as described by Ekoff et al. 
(4). Briefly, total bone marrow was harvested from the femora of sacrificed mice and 
cultured in complete RPMI medium (see above) supplemented with 10% of WEHI-3B 
conditioned medium (as a source of murine IL-3). Cells were re-plated weekly for 3 
weeks to dispose of adherent cells. In the fourth week of culture, murine stem cell factor 
(SCF) was added in the form of 10% of CHO/SCF(mm)-conditioned medium. A highly 
enriched population of murine mast cells was obtained, as judged by surface marker 
expression of c-KIT(CD117) and the high affinity receptor for immunoglobulin E, FcεRI. 
Cells were maintained in IL-3 and SCF-containing medium and all experiments were 
performed within 4 weeks after obtainment of enriched BMMC cultures. 
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Figure Legends To Supplementary Figures 
Supplementary Figure S1. BOK is widely expressed in mice (a) Quantitative RT-
PCR (qPCR) analysis of Bok mRNA levels in different mouse organs (mixed gender, 6-
12 weeks old): small intestine, colon, stomach, spleen, thymus, heart, kidney, liver, lung, 
pancreas, cerebellum, brain, ovaries, uterus (n=3) and hippocampus, caecum, 
duodenum, bone marrow, lymph nodes and placenta (n=2). Hprt served as the reference 
gene and values were normalized to Bok levels in the uterus. (b) BOK immunoblots of 
tissue lysates derived from C57BL/6 WT mice. Brain and pancreatic lysates from Bok-/- 
mice served as specificity control for the BOK antibody. Re-probing of the membrane 
with a GAPDH-specific antibody served as loading control.  
 
Supplementary Figure S2. 4-hydroxytamoxifen has no intrinsic cytotoxicity at the 
concentrations used. SV40-immortalized WT MEF and FDM were treated with various 
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concentrations of 4-hydroxytamoxifen (4-OHT) and cellular viability determined over time 
by FACS analysis (GFP-AnnexinV/PI exclusion). No cytotoxicity was detectable at 0.1 
µM 4-OHT, the concentration used to induce protein expression, or even at a ten-fold 
higher concentration of 1.0 µ M. Data are presented as means +/- SD from 3 
independent experiments. 
 
Supplementary Figure S3. Over-expressed BOK induces apoptosis in various cell 
lines. (a) FLAG-BOK was induced in WT FDM/5xUAS-FLAG-BOK cells by addition of 
0.1 µM 4-OHT, in the presence or absence of 25 µM Q-VD-OPh, and cell viability was 
determined by flow cytometry (GFP-Annexin V/PI exclusion). Anti-FLAG immunoblot of 
untreated and 4-OHT treated cells shows induction of FLAG-BOK at 24 h. Data are 
presented as means +/- SD from three independent experiments. (b) FLAG-BOK was 
induced as described in (a) in BAF/3-5xUAS-FLAG-BOK cells. Cell viability was 
measured at 24 and 48 h and caspase-3-/-7 activity was quantified by using the 
fluorogenic caspase activity assay at 24 h using DEVD-AMC as a substrate. BAF/3 cells 
deprived of IL-3 for 15 h served as a positive control for caspase-3 activation. Anti-FLAG 
and anti-caspase-3 immunoblots of BAF/3 cell lysates after 0, 16, 24, 36 and 48 h of 
FLAG-BOK induction. Viability data are presented as means +/- SD from three 
independent experiments. DEVDase data are presented as means from 2 independent 
experiments.  (c) Viability assay of Jurkat/5xUAS-FLAG-BOK cells after 0, 24, 48 and 72 
h of FLAG-BOK induction. Induction of FLAG-BOK was verified by Western blot analysis 
using anti-FLAG specific antibody. Data are presented as means +/- SD from three 
independent experiments. (d) Confocal scanning micrographs of HeLa cells transiently 
transfected with a pEGFP-BOK expression construct for 12 h and stained with anti-
cytochrome c antibody and Hoechst 33342 (nuclei). (e) Confocal scanning micrographs 
of HeLa cells transiently transfected with a FLAG-BOK/pcDNA3 expression construct for 
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18 h in the presence or absence of 25 µM Q-VD-OPh. Cells were stained with antibodies 
to FLAG and active caspase-3 specific and Hoechst 33342 dye. (f) FLAG-BOK was 
induced for 24 or 48 h in WT and Bok-/- SV40-immortalized MEF/5xUAS-FLAG-BOK 
cells and viability measured by flow cytometry (GFP-Annexin V/PI exclusion). 
Quantitative data are presented as means +/- SD of at least three independent 
experiments.  
 
Supplementary Figure S4. BOK present on vesicular structures partially co-
localizes with early and late endosomal markers. Confocal scanning micrographs of 
HeLa cells treated with 25 µM Q-VD-OPh and co-transfected for 21 h with expression 
constructs for FLAG-BOK/pcDNA3 (red) and early endosome/recycle marker 
RAB4Q67L-GFP (a), late endosome marker RAB5aQ97L-GFP (b), late 
endosome/lysosome marker RAB7Q67L-GFP (c) and early endosome marker 
RAB11Q70L-YFP (d). Constitutive active RAB mutants were used. Vesicular BOK 
partially co-localizes with the early endosome markers RAB4, RAB11 and with the late 
endosome marker RAB5a but not with the late endosome and lysosome marker RAB7 
as indicated by the white arrows. 
 
Supplementary Figure S5. Brefeldin A-induced Golgi fragmentation is independent 
of BOK. Confocal scanning micrographs of SV40-immortalized WT and Bok-/- MEF 
treated for the indicated times with brefeldin A (BFA, 5 µg/mL) and stained with an 
antibody against the cis-Golgi matrix protein GM130 (green). Nuclear DNA was stained 
with Hoechst 33342 dye (blue). 
 
Supplementary Figure S6. BOK-deficient cells respond normally to classical 
apoptotic stimuli. (a) SV40-immortalized WT and Bok-/- MEF were treated with the 
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indicated doses of tunicamycin, thapsigargin or etoposide for 24 h (dose responses). 
Cell survival was also examined over a period of 40 h for treatment with 0.1 µg/mL 
tunicamycin, in the presence or absence of 25 µM Q-VD-OPh. (b) WT and Bok-/- bone 
marrow-derived mast cells (BMMC) were treated with various doses of tunicamycin, 
thapsigargin, etoposide or staurosporine for 24 h. Apoptosis was also induced by 
withdrawal of IL-3 for 24 or 48 h. (c) WT and Bok-/- SCF-condHoxb8 immortalized myeloid 
progenitors were treated with tunicamycin, thapsigargin or etoposide for 18 h. Cell 
survival data (a-c) are shown as percentage of GFP-Annexin V/PI double-negative cells 
and presented as means +/- SD of at least three independent experiments. Significance 
was determined by unpaired student's t-Test (**p<0.01). 
 
Supplementary Figure S7. Enforced expression of FLAG-BOK leads to 
upregulation of the BH3-only proteins BIM and PUMA. SV40-immortalized WT 
MEF/5xUAS-FLAG-BOK (a) or WT FDM/5xUAS-FLAG-BOK (b) cells were treated with 
0.1 µM 4-OHT to induce FLAG-BOK expression. Total protein lysates were prepared at 
the indicated times and analyzed by Western blotting using antibodies against FLAG, 
BOK, BIM and PUMA. Re-probing of the membrane with an anti-Tubulin antibody served 
as loading control.	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Echeverry et al.  Supplementary Figure S1
Supplementary Figure S1. BOK is widely expressed in mice. (a) Quantitative RT-PCR (qPCR) of Bok mRNA 
levels in dierent mouse organs (mixed gender, 6-12 weeks old mice): small intestine, colon, stomach, spleen, 
thymus, heart, kidney, liver, lung, pancreas, cerebellum, brain, ovaries, uterus (n=3) and hippocampus, 
caecum, duodenum, bone marrow, lymph nodes and placenta (n=2). Hprt served as reference gene and 
values were normalized to Bok levels in the uterus. (b) BOK immunoblots of tissue lysates derived from 
C57BL/6 WT mice. Brain and pancreatic lysates from Bok-/- mice served as specicity control for the BOK anti-
body. Re-probing of the membrane with a GAPDH-specic antibody served as loading control. 
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Supplementary Figure S2. 4-hydroxytamoxifen has no intrinsic cytotoxicity at the con-
centrations used. SV40-immortalized WT MEF and FDM were treated with various concen-
trations of 4-hydroxytamoxifen (4-OHT) and cellular viability determined over time by FACS 
analysis (GFP-AnnexinV/PI exclusion). No cytotoxicity was detectable at 0.1 µM 4-OHT, the 
concentration used to induce protein expression, or even at a ten-fold higher concentration 
of 1.0 µM. Data are presented as means +/- SD from 3 independent experiments.
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Supplementary Figure S3. Over-expressed BOK induces apoptosis in various cell lines. (a) FLAG-BOK was 
induced in WT FDM/5xUAS-FLAG-BOK cells by addition of 0.1 µM 4-OHT, in the presence or absence of 25 µM Q-VD-
OPh, and cell viability was determined by flow cytometry (GFP-Annexin V/PI exclusion). Anti-FLAG immunoblot of 
untreated and 4-OHT treated cells shows induction of FLAG-BOK at 24 h. Data are presented as means +/- SD from three 
independent experiments. (b) FLAG-BOK was induced as described in (a) in BAF/3-5xUAS-FLAG-BOK cells. Cell viability 
was measured at 24 and 48 h and caspase-3-/-7 activity was quantified by using the fluorogenic caspase activity assay at 
24 h using DEVD-AMC as a substrate. BAF/3 cells deprived of IL-3 for 15 h served as a positive control for caspase-3 
activation. Anti-FLAG and anti-caspase-3 immunoblots of BAF/3 cell lysates after 0, 16, 24, 36 and 48 h of FLAG-BOK 
induction. Viability data are presented as means +/- SD from three independent experiments. DEVDase data are 
presented as means from 2 independent experiments.  (c) Viability assay of Jurkat/5xUAS-FLAG-BOK cells after 0, 24, 48 
and 72 h of FLAG-BOK induction. Induction of FLAG-BOK was verified by Western blot analysis using anti-FLAG specific 
antibody. Data are presented as means +/- SD from three independent experiments. (d) Confocal scanning micrographs 
of HeLa cells transiently transfected with a pEGFP-BOK expression construct for 12 h and stained with anti-cytochrome c 
antibody and Hoechst 33342 (nuclei). (e) Confocal scanning micrographs of HeLa cells transiently transfected with a 
FLAG-BOK/pcDNA3 expression construct for 18 h in the presence or absence of 25 µM Q-VD-OPh. Cells were stained 
with antibodies to FLAG and active caspase-3 specific and Hoechst 33342 dye. (f) FLAG-BOK was induced for 24 or 48 
h in WT and Bok-/- SV40 immortalized MEF/5xUAS-FLAG-BOK cells and viability measured by flow cytometry (GFP-
Annexin V/PI exclusion). Quantitative data are presented as means +/- SD of at least three independent experiments.
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Supplementary Figure S4. BOK present on vesicular structures partially co-localizes with early 
and late endosomal markers. Confocal scanning micrographs of HeLa cells treated with 25 µM 
Q-VD-OPh and co-transfected for 21 h with expression constructs for FLAG-BOK/pcDNA3 (red) and 
early endosome/recycle marker RAB4Q67L-GFP (a), late endosome marker RAB5aQ97L-GFP (b), late 
endosome/lysosome marker RAB7Q67L-GFP (c) and early endosome marker RAB11Q70L-YFP (d). 
Constitutive active RAB mutants were used. Vesicular BOK partially co-localizes with the early endo-
some markers RAB4, RAB11 and with the late endosome marker RAB5a but not with the late endo-
some and lysosome marker RAB7 as indicated by the white arrows.
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Supplementary Figure S5. Brefeldin A-induced Golgi fragmentation is independent of BOK. 
Confocal scanning micrographs of SV40 immortalized WT and Bok-/- MEF treated for the indi-
cated times with brefeldin A (BFA, 5 µg/mL) and stained with an antibody against the cis-Golgi 
matrix protein GM130 (green). Nuclear DNA was stained with Hoechst 33342 dye (blue).
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Supplementary Figure S6. BOK-decient cells respond normally to classical apoptotic stimuli. (a) SV40 immortalized 
WT and Bok-/- MEF were treated with the indicated doses of tunicamycin, thapsigargin or etoposide for 24 h (dose responses). 
Cell survival was also examined over a period of 40 h for treatment with 0.1 µg/mL tunicamycin, in the presence or absence 
of 25 µM Q-VD-OPh. (b) WT and Bok-/- bone marrow derived mast cells (BMMC) were treated with various doses of tunicamy-
cin, thapsigargin, etoposide or staurosporine for 24 h. Apoptosis was also induced by withdrawal of IL-3 for 24 or 48 h. (c) WT 
and Bok-/- SCF-condHoxb8 immortalized myeloid progenitors were treated with tunicamycin, thapsigargin or etoposide for 
18 h. Cell survival data (a-c) are shown as percentage of GFP-Annexin V/PI double-negative cells and presented as means +/- 
SD of at least three independent experiments. Signicance was determined by unpaired student's t-Test (**p<0.01).
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Supplementary Figure S7. Enforced expression of FLAG-BOK leads to upregulation of the BH3-only 
proteins BIM and PUMA. SV40-immortalized WT MEF/5xUAS-FLAG-BOK (a) or WT FDM/5xUAS-FLAG-
BOK (b) cells were treated with 0.1 µM 4-OHT to induce FLAG-BOK expression. Total protein lysates were 
prepared at the indicated times and analyzed by Western blotting using antibodies against FLAG, BOK, 
BIM and PUMA. Re-probing of the membrane with an anti-Tubulin antibody served as loading control.
